Member Info for mizman

With the delivery of the government machines a few weeks ago, I would hope we are producing the test now and just waiting on official announcement.

?? Stu!

And yes, we can confirm delivery of new UK Government-loaned equipment.

These are, after all, *very* busy times as we prepare our Alva HQ for the production of a government-selected lateral flow test.

#ODX
https://t.co/zHWnuARis1

We are pleased to announce an agreement to continue to explore future agreements.

It's a sure sign that the stars are aligning (justification for salary until next placement) and an important intermediate step towards the next agreement.

https://publichealthmatters.blog.gov.uk/2021/07/27/how-we-can-continue-to-protect-ourselves-each-other-and-reduce-the-spread-of-covid-19/

Continue to use LFD tests regularly. LFD tests can help determine whether you are carrying the virus without any symptoms and the tests are currently available for free to everyone and can be ordered online or collected from many local pharmacies. It is estimated that around 1 in 3 people with COVID-19 do not have symptoms but can still pass the infection on to other people. Many people are regularly testing to help protect themselves and their communities, and it is particularly important if you spend time with people who are more vulnerable to severe illness, and who may not have been able to have a COVID vaccine.

That's changing. Beer money has all gone, so I suspect on the next RNS, expect them to frantically chase the SP on the way up.

Starmer wants to be ‘pragmatic’ over Covid passport proposals
Sir Keir Starmer has said he wants to be “pragmatic” over proposals on the use of Covid passports.

He told LBC: “I think tests are actually more useful than double vaccinations, as the Health Secretary has shown. He, of course, got Covid just about 10 days ago now, I know he’s through it now, but he had been double vaccinated. So, I actually think tests are much more useful.

“I think that the idea that we can go back to mass sporting events or other events without any checks is not one I would subscribe to.”

Can only be one logical explanation.

The consortium ABC-19 test is a far superior product than Thriva, hence government naturally selecting the more expensive and ****e test.

How else do you get a kickback?

It's the festival of sacrifice today. Metaphorically speaking, a few trolls and shorters are about to be slaughtered.

Register now for our VISITECT® CD4 Advanced Disease interactive webinars.

19 July. Improving access to same-day CD4 testing
https://t.co/uOoC8EQouF

20 July. Global studies and our commitment to product support
https://t.co/Z46xydMsrT

https://t.co/n1FfeDswXp

#IAS2021 https://t.co/msIDkParlq

Yes great own goal by bozo. Everyone wants to be on the ping free pilot. Millions of daily LFT are required.

#ABDX updates from this week

#antibodytests & #covidpass strategy challenges: https://t.co/CYnNEwnOPz

Dr Jenny Harries mentions #antibodytesting in select committee https://t.co/upmHpDmrT6 (11:22)

PM caution despite vaccine rollout & restriction easing https://t.co/y6myRqXp7J https://t.co/OWtFGt5AKz

Looks like the government are about to spend the unused budget, especially to determine antibodies levels post vaccination.

I wonder how much of that will come to ODX?

As I said earlier. How many will be buying back in or topping up today? £374M CONTRACT is a compelling reason.

From today's RNS :

The focus of the market currently is on antigen testing as a key tool to manage the pandemic and we were pleased to announce the signing of a contract with the Department of Health and Social Care ("DHSC") in contemplation of manufacturing selected tests on behalf of DHSC to meet the UK Government's desire for UK-manufactured product. We had hoped that the Mologic test would be chosen by the DHSC as a UK-developed test to be made by us as UK manufacturers, however the contract itself is test agnostic and we are prepared to manufacture whichever test is chosen. The ability to supply tests that are produced within the UK remains a key priority for DHSC and to that end they have facilitated discussions with other potential partner companies with lateral flow antigen tests that have now been approved by the DHSC and also have self-test approval. We have already concluded technical diligence with these parties and we are confident that the transfer time can be expedited given that they have tests already working at scale, rather than transferring straight from development.

How many will be buying back in or topping up today? £374M CONTRACT is a compelling reason.

Prosecco refer to the statement issued last night (12th July) by Johanna Churchill, the Parliamentary Under-Secretary of State at the Department of Health and Social Care.

She stated in writing the following: "The Government continues to explore different operating models to make best use of the capacity created in the United Kingdom diagnostics manufacturing industry. There are a number of ongoing conversations between Global Access Diagnostics, Omega and third party test developers which we hope will provide opportunities to further increase UK manufacturing output of lateral flow tests".

We have a little more news to share regarding both the @DHSCgovuk contract and home-use CE marking.

?? DHSC update

?? Manufacturing contract is test agnostic
?? DHSC arranged commercial discussions with partner companies with antigen tests that have self-test approval
?? Technical diligence is complete
?? Expect rapid tech transfer (tests are already working at scale)
#ODX

?? Home-use CE marking

?? Utilisation studies started
?? Data submission to notified body by the end July
?? Potential (with self-test approval) that VISITECT®? would be available for future DHSC purchase as a UK developed/made test

#ODX

The focus of the market currently is on antigen testing as a key tool to manage the pandemic and we were pleased to announce the signing of a contract with the Department of Health and Social Care ("DHSC") in contemplation of manufacturing selected tests on behalf of DHSC to meet the UK Government's desire for UK-manufactured product. We had hoped that the Mologic test would be chosen by the DHSC as a UK-developed test to be made by us as UK manufacturers, however the contract itself is test agnostic and we are prepared to manufacture whichever test is chosen. The ability to supply tests that are produced within the UK remains a key priority for DHSC and to that end they have facilitated discussions with other potential partner companies with lateral flow antigen tests that have now been approved by the DHSC and also have self-test approval. We have already concluded technical diligence with these parties and we are confident that the transfer time can be expedited given that they have tests already working at scale, rather than transferring straight from development.

https://twitter.com/pk_wendall/status/1414660993918148610?s=19

Question
"To ask the Secretary of State for Health and Social Care, when the Government plans announce its choice of British lateral flow test after the signing of contracts in March 2021 with Omega Diagnostics and Global Access Diagnostics in order to meet the target of having the majority of UK lateral flow tests produced in the UK."

Answer
"The Government continues to explore different operating models to make best use of the capacity created in the United Kingdom diagnostics manufacturing industry. There are a number of ongoing conversations between Global Access Diagnostics, Omega and third party test developers which we hope will provide opportunities to further increase UK manufacturing output of lateral flow tests."

https://questions-statements.parliament.uk/written-questions/detail/2021-06-18/18511

Question
Martin Vickers
Conservative
Cleethorpes
Commons

To ask the Secretary of State for Health and Social Care, when the Government plans announce its choice of British…

Answer
Jo Churchill
Conservative
Bury St Edmunds
Commons
Answered on
12 July 2021

The Government continues to explore different operating models to make best use of the capacity created in the United Kingdom diagnostics manufacturing industry. There are a number of ongoing conversations between Global Access Diagnostics, Omega and third party test developers which we hope will provide opportunities to further increase UK manufacturing output of lateral flow tests.

Answered by
Department of Health and Social Care